Organization
Aix Marseille University - Assistance Publique Hopitaux De Marseille
4 abstracts
Abstract
Friendly-user score assessing gut dysbiosis and resistance to immune checkpoint inhibitors (ICI).Org: Department of Medical, Surgical and Health Sciences, University of Trieste, Medical Oncology, Azienda Ospedaliera Universitaria Integrata di Verona, Thoracic Oncology Department & CIC Inserm 1425, Hôpital Bichat Claude Bernard, AP-HP.Nord, Foch Hospital, Centre Hospitalier Universitaire de Grenoble (France),
Abstract
Phase 1/2 study of tusamitamab ravtansine in patients with advanced solid tumors: Pooled safety analysis of corneal adverse events.Org: Gustave Roussy Département d'Organisation du Parcours Patient, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Institut Bergonié, Aix Marseille University - Assistance Publique Hopitaux De Marseille, Université Paris Saclay,
Abstract
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.Org: Aix Marseille University - Assistance Publique Hopitaux De Marseille, APHM, Service d'Oncologie Multidisciplinaire & Innovations Thérapeutiques, Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance, CNRS UMR 5309-INSERM U1209, CRCM,
Abstract
Clinical benefit of personalized treatment following high throughput sequencing in metastatic melanoma: A national retrospective study.Org: Dermatology and Skin Cancer Department, AP-HM Marseille, Dermatology Departement, Cochin Hospital, APHP,Université Paris Cité, Paris, France, CHU de Bordeaux, Cochin Hospital,